Risk of long QT syndrome in novel coronavirus COVID-19

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The article is devoted to the risk of cardiovascular disease in coronavirus infection. In March 2020, the World Health Organization announced the COVID-19 pandemic. The virus set many tasks for practicing doctors, inclu­ding the study of its pathogenesis and the creation of a therapy suitable for all patient groups. This paper presents information about cellular entry of the coronavirus, the development of cardiovascular diseases, in particular, the heart, and the latest data on experimental therapy with hydroxychloroquine. Coronavirus has been shown to affect the synthesis of angiotensin 2, which increase the QT interval. At the same time, the combination therapy ­using chloroquine and azithromycin caused a critical prolongation of the QT interval in some cases. On 4 July 2020, WHO accepted the Solidarity Trial’s International Steering Committee recommendation has stop the trial of these drugs. Cardiologists should review the latest information on the effects of coronavirus on the cardiovascular system and based on this, make recommendations the management and treatment of severe patients.


Full Text

Restricted Access

About the authors

V N Oslopov

Kazan State Medical University

Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

J V Oslopova

Kazan (Volga Region) Federal University

Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

E V Hazova

Kazan State Medical University

Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

K S Sergienko

Kazan State Medical University

Author for correspondence.
Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

A F Murzakhanova

Kazan State Medical University

Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

J M Boichuk

Kazan State Medical University

Email: kostya_s99@mail.ru

Russian Federation, Kazan, Russia

References

  1. Stokes E.K., Zambrano L.D., Anderson K.N. et al. Coronavirus disease 2019 case surveillance — United States, January 22 — May 30, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020; 69; 759–765. doi: 10.15585/mmwr.mm6924e2.
  2. Kuba K., Imai Y., Rao S. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005; 11 (8): 875–879. doi: 10.1038/nm1267.
  3. Vardanyan Ya.T. COVID-19 and increased risk of ventricular arrhythmias in patients with long QT syndrome). Molodoy uchenyy. 2020; (14): 99–102. (In Russ.)
  4. Khashkhusha T.R., Chan J.S.K., Harky A. ACE inhibitors and COVID-19: We don't know yet. J. Card. Surg. 2020; 35 (6): 1172–1173. doi: 10.1111/jocs.14582.
  5. Greber U.F., Singh I., Helenius A. Mechanisms of virus uncoating. Trends Microbiol. 1994; 2 (2): 52–56. doi: 10.1016/0966-842x(94)90126-0.
  6. Oslopova Yu.V., Oslopov V.N. Ekstrasistoliya (sostoyanie problemy, membrannye aspekty patogeneza i lecheniya). (Extrasystole (state of the problem, membrane aspects of pathogenesis and treatment).) Monograph. Kazan: Meddok. 2012; 300 p. (In Russ.)
  7. published online ahead of print, 2020 Mar 31 doi: 10.1016/j.hrthm.2020.03.024.
  8. Zhou D., Dai S.M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemo­ther. 2020; 75 (7): 1667–1670. doi: 10.1093/jac/dkaa114.
  9. White N.J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 2007; 7 (8): 549–558. doi: 10.1016/S1473-3099(07)70187-1.
  10. Liu J., Cao R., Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhi­biting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6: 16. doi: 10.1038/s41421-020-0156-0.
  11. Ramireddy A., Chugh H., Reinier K. et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: Implications for QT interval monitoring. J. Am. Heart Assoc. 2020; 9 (12): e017144. doi: 10.1161/JAHA.120.017144.
  12. Mitra R.L., Greenstein S.A., Epstein L.M. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with ­either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Heart Rhythm. Case Rep. 2020; 6 (5): 244–248. doi: 10.1016/j.hrcr.2020.03.016.
  13. Kolotsei L.V., Snezhitskiy V.A., Ardashev A.V. Coronavirus disease (COVID-19) treatment algorithms in patients with QT interval prolongation. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2020; 18 (2): 203–210. (In Russ.) doi: 10.25298/2221-8785-2020-18- 2-203-210.
  14. Shlyakhto E.V., Konradi A.O., Villeval'de S.V. et al. Rukovodstvo po diagnostike i lecheniyu bolezney sistemy krovoobrashcheniya (BSK) v kontekste pandemii COVID-19 (kratkaya versiya). (Guidelines for the diagnosis and treatment of circulatory system disorders (CVD) in the context of the COVID-19 pandemic (short version).) 2020; 10. https://scardio.ru/content/Guidelines/COVID-19.pdf (access date: 15.08.2020). (In Russ.)
  15. Sapp J.L., Alqarawi W., MacIntyre C.J. et al. Gui­dance on minimizing risk of drug-induced ventricular arrhy­thmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society. Can. J. ­Cardiol. 2020; 36 (6): 948–951. doi: 10.1016/j.cjca.2020.04.003.

Statistics

Views

Abstract - 35

PDF (Russian) - 1

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


© 2020 Oslopov V.N., Oslopova J.V., Hazova E.V., Sergienko K.S., Murzakhanova A.F., Boichuk J.M.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies